Navigation Links
New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis

MENLO PARK, Calif., March 2 /PRNewswire/ -- A recently published study in the American Journal of Rhinology and Allergy demonstrates Balloon Sinuplasty™ technology to be safe when used by physicians in pediatric patients. Known as the INTACT study, this is a prospective, non-randomized, multicenter study and was sponsored by Acclarent, Inc.

Thirty-two pediatric patients, between the ages of 2 and 11, underwent minimally invasive sinus surgery with the Balloon Sinuplasty™ technology after previously failing medical management for 3-6 months and showing CT evidence of chronic sinusitis. These patients were followed for one year and effectiveness was assessed using the validated SN-5 quality of life questionnaire.

At one year follow up, 87% of patients reported improvement in their sinus symptoms. Statistically significant improvements in patient quality of life were maintained through one year.  No adverse events were observed at any time point throughout the study.  The authors concluded that when patients are appropriately selected, preliminary results indicate that sinus ostial dilation using balloon catheters in children has an excellent safety profile and may be an effective minimally invasive treatment option to relieve sinus ostial obstruction.

Balloon Sinuplasty™ technology is used to restore normal sinus drainage by widening constricted sinus passages with specially designed catheters and balloons.  The technology has been used to treat over 100,000 patients since receiving FDA clearance in 2005 and can be used alone or with standard surgical instrumentation.  Since 2005, more than 5,600 sinus surgeons have been trained on the use of Balloon Sinuplasty™ technology.

The Center for Disease Control data reports sinusitis is among the most common illnesses in the U.S., affecting an estimated 37 million Americans and leading to 500,000 surgeries a year.  Pediatric patients make up 22% of all office visits for chronic sinusitis(1).  Symptoms include repeated infections, headaches, facial pain, persistent congestion, cough and fatigue.

"The INTACT study affirms the safety of minimally invasive sinus surgery with Balloon Sinuplasty™ technology in children. The use of Balloon Sinuplasty™ technology at the time of adenoidectomy or after failed adenoidectomy is an option that should be considered prior to traditional sinus surgery," said Hassan Ramadan, M.D., MSc, FACS of West Virginia University, and lead author of the INTACT study.

All medical procedures contain risks.  Although rare, the risks associated with Balloon Sinuplasty™ technology include tissue and mucosal trauma, infection, or possible optic injury.  Consult your physician for a full discussion of risks and benefits to determine whether this procedure is right for you or your child.

About Acclarent

Acclarent, Inc., a business unit of Ethicon, Inc. (, is a medical device company located in Menlo Park, CA.  Its singular focus is improving patient care in all areas of otolaryngology by designing, developing and commercializing medical devices that address conditions affecting the ear, nose and throat (ENT).  Acclarent is demonstrating this by developing innovative technologies, and investing in clinical studies and physician training. For more information, visit or

American Journal of Rhinology & Allergy, Volume 24, Number 1, January/February 2010 , pp. e54-e56(1)

(1) Benninger, M., Otolaryngology Head and Neck Surgery 2003; 129S: S1-S32

SOURCE Acclarent, Inc.

Back to top



SOURCE Acclarent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... Ruth Pearson ... brutal lupus flare-up. Unable to walk without assistance and quickly losing hope of recovering ... then a miracle happened. , Pearson was attending a women’s retreat when she experienced ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... 01, 2015 , ... December 1, 2015 -- InstantLabs is ... growing product line of food safety and seafood fraud prevention tools. , The ... allow InstantLabs to offer fast, reliable species identification for the four most popular ...
Breaking Medicine News(10 mins):